Idelvion (Coagulation factor IX [recombinant], albumin fusion protein) for Hemophilia

Overview
Idelvion is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor IX deficiency due to hemophilia B. Idelvion can also be used for perioperative (before, during, and after surgery) care and for routine prophylaxis. The technical name of Idelvion is Coagulation factor IX [recombinant], albumin fusion protein.

Idelvion is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that Idelvion is given as an intravenous injection.

Idelvion comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Idelvion lists common side effects including headache.

Rare but serious side effects listed for Idelvion include life-threatening hypersensitivity reactions and the development of inhibitors.

For more details about this treatment, visit:

Idelvion.com